XM does not provide services to residents of the United States of America.
D
D

DassaultSystem

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

ABB, Klepierre, Ryanair

EUROPE RESEARCH ROUNDUP-ABB, Klepierre, Ryanair June 20 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including ABB, Klepierre and Ryanair, on Thursday. HIGHLIGHTS * ABB Ltd ABBN.S : Citigroup cuts to neutral from buy * ASM International NV ASMI.AS : Morgan Stanley raises to overweight from equal weight * Deutsche Lufthansa AG LHAG.DE : Stifel cuts to hold from buy * Klepierre LOIM.PA : HSBC raises to buy from hold * Ryanair RYA.I : UBS cu
A
A
B
C
D
D
G
K
K
L
L
L
M
N
N
P
S
W
A
A
A
L
R
S

Mahindra & Mahindra Selects Dassault Systèmes' 3Dexperience Platform on Cloud

BRIEF-Mahindra & Mahindra Selects Dassault Systèmes' 3Dexperience Platform on Cloud June 20 (Reuters) - Dassault Systemes SE DAST.PA : 3DEXPERIENCE PLATFORM ON THE CLOUD SELECTED BY MAHINDRA & MAHINDRA AS IT ACCELERATES ITS DIGITAL TRANSFORMATION Source text for Workspace: ID:nGNE2k05lD Further company coverage: DAST.PA (Gdansk Newsroom)
D

Exane sees Dassault Systemes five-year targets under pressure

BUZZ-Exane sees Dassault Systemes five-year targets under pressure ** Exane BNP Paribas cuts Dassault Systemes DAST.PA to "underperform" from "neutral" saying that growing competition and difficulties in ongoing business model transition put the French software provider's five-year targets under pressure ** The brokerage says competition in mass-ma
D
F

Hargreaves Lansdown, Segro, Umicore

EUROPE RESEARCH ROUNDUP-Hargreaves Lansdown, Segro, Umicore June 19 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Hargreaves Lansdown, Segro and Umicore, on Wednesday. HIGHLIGHTS * GEA Group AG G1AG.DE : Jefferies raises to buy from hold * Hargreaves Lansdown HRGV.L : Jefferies cuts to hold from buy * Oxford Instruments OXIG.L : Berenberg raises target price to 2,945p from 2,640p * Segro SGRO.L : Jefferies cuts to hold from buy *
A
A
B
B
B
B
B
B
B
D
D
G
G
G
G
G
H
H
I
K
K
L
M
R
S
S
S
U
U
V
A
S

Medidata Launches Clinical Data Studio, Leveraging AI To Modernize The Data Experience In Clinical Trials

BRIEF-Medidata Launches Clinical Data Studio, Leveraging AI To Modernize The Data Experience In Clinical Trials June 18 (Reuters) - Dassault Systemes SE DAST.PA : MEDIDATA LAUNCHES CLINICAL DATA STUDIO, LEVERAGING AI TO MODERNIZE THE DATA EXPERIENCE IN CLINICAL TRIALS Source text for Eikon: ID:nBw8gtMQta Further company coverage: DAST.PA
D

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.